Kaur Manleen, Singh Neetu
Centre for Biomedical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, India.
All India Institute of Medical Sciences, Biomedical Engineering Unit, Ansari Nagar, New Delhi 110029, India.
ACS Appl Bio Mater. 2025 Jul 21;8(7):5496-5511. doi: 10.1021/acsabm.5c00545. Epub 2025 Jul 8.
Liver cirrhosis, a progressive disease caused by chronic liver conditions, significantly increases the risk of sepsis due to immune dysfunction. The overlapping symptoms of cirrhosis and sepsis make early diagnosis particularly challenging, emphasizing the need for reliable biomarker diagnostic tools. Conventional methods are slow and result in delayed treatment, deteriorating liver function in cirrhotic patients over time. Electrochemical biosensors have emerged as promising solutions, offering rapid and precise detection of both host- and pathogen-related proteins. These platforms overcome many limitations of traditional diagnostic methods, providing enhanced sensitivity and specificity. Furthermore, the ability of the electrochemical platform to simultaneously detect multiple biomarkers has improved the sensor's reliability for comprehensive point-of-care diagnostics in clinical settings. Despite challenges, such as standardizing diagnostic thresholds and addressing operational barriers, electrochemical sensors have the potential to transform the detection and management of sepsis in liver cirrhosis. This perspective highlights the potential of the electrochemical platforms established over time to improve diagnostic precision and therapeutic strategies in managing liver-related bacterial sepsis.
肝硬化是一种由慢性肝脏疾病引起的进行性疾病,由于免疫功能障碍,显著增加了败血症的风险。肝硬化和败血症的重叠症状使得早期诊断极具挑战性,这凸显了对可靠生物标志物诊断工具的需求。传统方法速度慢,导致治疗延迟,随着时间的推移,肝硬化患者的肝功能会恶化。电化学生物传感器已成为有前景的解决方案,能够快速、精确地检测宿主和病原体相关蛋白。这些平台克服了传统诊断方法的许多局限性,提供了更高的灵敏度和特异性。此外,电化学平台同时检测多种生物标志物的能力提高了传感器在临床环境中进行全面即时诊断的可靠性。尽管存在诸如标准化诊断阈值和解决操作障碍等挑战,但电化学生物传感器有潜力改变肝硬化败血症的检测和管理。这一观点强调了随着时间推移建立的电化学平台在提高肝脏相关细菌性败血症的诊断精度和治疗策略方面的潜力。